Shares of Sarepta Therapeutics Inc. (Nasdaq: SRPT) continued climbing by gaining $1.42 to close at $15.82 after a news report yesterday highlighted positive results in a small, mid-stage trial of the company's Duchenne Muscular Dystrophy treatment Eteplirsen.